GENITOURINARY CANCERS

Latest News

FDA Fast Tracks 225Ac-FL-020 in mCRPC
FDA Fast Tracks 225Ac-FL-020 in mCRPC

July 3rd 2024

The FDA has granted fast track designation to 225Ac-FL-020, a promising PSMA-targeting radionuclide drug conjugate for metastatic castration-resistant prostate cancer.

FDA Approves FoundationOne Liquid CDx for Niraparib/Abiraterone in Aggressive Prostate Cancer
FDA Approves FoundationOne Liquid CDx for Niraparib/Abiraterone in Aggressive Prostate Cancer

July 1st 2024

Long-Term Data Supports Nadofaragene Firadenovec in High-Risk NMIBC
Long-Term Data Supports Nadofaragene Firadenovec in High-Risk NMIBC

June 28th 2024

UGN-102 Delivers High 12-Month DOR in Non-Muscle Invasive Bladder Cancer
UGN-102 Delivers High 12-Month DOR in Non-Muscle Invasive Bladder Cancer

June 17th 2024

Phase 3 SunRISe-2 Study Investigates Novel TAR-200 Therapy in Muscle Invasive Bladder Cancer
Phase 3 SunRISe-2 Study Investigates Novel TAR-200 Therapy in Muscle Invasive Bladder Cancer

June 16th 2024

More News